Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies

Clin Lymphoma Myeloma Leuk. 2021 May;21(5):e483-e487. doi: 10.1016/j.clml.2021.01.003. Epub 2021 Jan 12.

Authors

Affiliations

¹ Section of Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, New Haven, CT.
² Department of Hematology and Oncology, H. Lee Moffitt Cancer Center, Tampa, FL.
³ Department of Biostatistics, Yale School of Public Health, New Haven, CT.
⁴ Section of Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, New Haven, CT. Electronic address: [email protected].

PMID: 33551344
DOI: 10.1016/j.clml.2021.01.003

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Aged, 80 and over
Humans
Immune Checkpoint Inhibitors / pharmacology
Immune Checkpoint Inhibitors / therapeutic use*
Middle Aged
Myeloproliferative Disorders / drug therapy*

Substances

Immune Checkpoint Inhibitors

Grants and funding

P30 CA016359/CA/NCI NIH HHS/United States